02269.HK
WuXi Biologics (Cayman) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 49.18
−3.00%Year over year
Reported trailing growth
- Revenue
- +29.2%
- EBITDA
- +71.9%
- EBIT
- +77.1%
- EPS
- +42.6%
- Free cash flow
- +489.5%
- Operating cash flow
- +2.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +12.6%
- EBITDA
- +8.4%
- EBIT
- +15.2%
- Net income
- +3.6%
- EPS
- +3.1%
- Free cash flow
- +153.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026